TWi Biotechnology, Inc. (TPEX:6610)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.80
-0.80 (-2.53%)
Oct 9, 2025, 2:59 PM CST
-2.53%
Market Cap3.31B
Revenue (ttm)n/a
Net Income (ttm)-155.28M
Shares Out107.63M
EPS (ttm)-1.77
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,442,747
Average Volume1,629,982
Open32.50
Previous Close31.60
Day's Range29.90 - 32.65
52-Week Range8.96 - 40.85
Beta0.59
RSI50.19
Earnings DateNov 13, 2025

About TWi Biotechnology

TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises AC-203, which is in Phase 2 clinical trial for various indications, including epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus; and AC- 1101, which is in Phase 1 trial for the treatment of vitiligo and preclinical stage for the treatment of atopic dermatitis, as well as granuloma annulare and rare autoimmune skin diseas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 23
Stock Exchange Taipei Exchange
Ticker Symbol 6610
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.